BIBR 953 ZW in Healthy Elderly Subjects

NCT ID: NCT02173730

Last Updated: 2014-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-11-30

Brief Summary

To assess the steady state pharmacokinetic profile of BIBR 953 ZW after administration of BIBR 1048 to male and female elderly subjects, to assess pharmacokinetic gender differences. To assess the effect of coadministration of Pantoprazole on the bioavailability of BIBR 953 ZW.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

BIBR 1048 MS without Pantoprazole

150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day

Group Type: EXPERIMENTAL

BIBR 1048 MS

Intervention Type: DRUG

BIBR 1048 MS capsule 150 mg

BIBR 1048 MS with Pantoprazole

150 mg BIBR 1048 MS capsules administered twice daily over 6 days and once in the morning of the seventh day together with Pantoprazole. Pantoprazole administration (40 mg bid) started two days before administration og BIBR 1048 and ended in the morning of the seventh day.

Group Type: EXPERIMENTAL

BIBR 1048 MS

Intervention Type: DRUG

BIBR 1048 MS capsule 150 mg

Pantoprazole

Intervention Type: DRUG

Pantoprazole tablet 40 mg

Interventions

BIBR 1048 MS

BIBR 1048 MS capsule 150 mg

Intervention Type: DRUG

Pantoprazole

Pantoprazole tablet 40 mg

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy male and female elderly subjects as determined by results of screening
• Signed written informed consent in accordance with GCP and local legislation
• Age ≥ 65, no upper limit
• BMI ≥ 18.5 and ≤ 29.9 kg/m2

Exclusion Criteria

• Any finding at the medical examination (including blood pressure, pulse rate and ECG) deviating from normal and of clinical relevance
• Clinically relevant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
• History of relevant orthostatic hypotension, fainting spells and blackouts
• Diseases of the central nervous system (such as epilepsy) or psychiatric disorders
• Chronic or relevant acute infections
• History of

• allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
• any bleeding disorder including prolonged or habitual bleeding
• other hematologic disease
• cerebral bleeding (e.g. after a car accident)
• cranio-cerebral trauma
• Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
• Use of any drugs that might influence the results of the trial within 10 days prior to administration or during the trial
• Participation in another trial with an investigational drug within 2 months prior to administration or during trial
• Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
• Alcohol intake (>30 - 40 g/day)
• Drug abuse
• Blood donation within 1 month prior to administration or during the trial
• Excessive physical activities within 5 days prior to administration or during the trial
• Any laboratory value outside the clinically accepted reference range
• History of any familial bleeding disorder
• Thrombocytes < 140000/μl (male) or < 156000/μl (female)

• Minimum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

1160.10

Identifier Type: -

Identifier Source: org_study_id